Cancer Treatment Centers of America in Arizona Purchases BSD-2000 Hyperthermia System from BSD Medical

pan>)--BSD Medical Corporation (NASDAQ: BSDM) (Company or BSD) (www.BSDMedical.com),
a leading provider of medical systems that utilize targeted heat therapy
to treat cancer, announced today that the Cancer Treatment Centers of
America (CTCA) at Western Regional Medical Center (WRMC),
located in Goodyear, Arizona, has purchased a BSD-2000 Hyperthermia
System (BSD-2000). WRMC serves the Western United States, including the
major metropolitan areas of Phoenix,
Denver,
Los
Angeles, Las
Vegas, Seattle, Portland and Albuquerque.
This will be the eighth BSD Hyperthermia system purchased by CTCA.
“offering
the very best in cancer care.”
WRMC is a state-of-the-art, all-digital cancer hospital that provides
advanced cancer treatments, world-class technologies and integrative
therapies under one roof. The 213,000-square-foot facility is located on
a 25-acre site, which is part of the Phoenix metropolitan area. Like the
other CTCA cancer hospitals, WRMC provides the most advanced therapeutic
resources in cancer treatment (http://www.cancercenter.com/western-hospital/about-western/history.cfm).
CTCA is a network of hospitals and one of the premier providers of
cancer care in the world. CTCA physicians specialize in treating many types
of cancer, including complex and advanced stage cases. CTCA is
committed to revolutionizing cancer care by providing the most advanced
and effective cancer treatments and integrative therapies available in
order to treat the cancer and improve the patients treatment experience
and quality of life. The CTCA hospitals were recently recognized by the
Commission on Cancer of the American College of Surgeons as offering
the very best in cancer care.
About the BSD-2000 Hyperthermia System
The BSD-2000 developed and patented exclusively by BSD delivers
localized therapeutic heating (hyperthermia) by applying radiofrequency
(RF) energy. The BSD-2000 creates a central focusing of energy that can
be electronically focused to target the shape, size, and location of the
tumor, thus providing dynamic control of the heating delivered to the
tumor region. The BSD-2000 has Humanitarian Device Exemption (HDE)
marketing approval from the U.S. Food and Drug Administration (FDA) for
use in conjunction with radiation therapy for the treatment of cervical
cancer patients who are ineligible for chemotherapy. The BSD-2000 also
has CE (Conformit Europenne) Marking approval for the commercial sale
in Europe. CE Marking approval is also recognized in many countries
outside of the EU.
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and services
systems to treat cancer and benign diseases using heat therapy delivered
using focused radiofrequency (RF) and microwave energy. BSDs product
lines include both hyperthermia and ablation treatment systems. BSDs
hyperthermia cancer treatment systems, which have been in use for
several years in the United States, Europe and Asia, are used to treat
certain tumors with heat (hyperthermia) while increasing the
effectiveness of other therapies such as radiation therapy. BSDs
microwave ablation system has been developed as a stand-alone therapy to
employ precision-guided microwave energy to ablate (destroy) soft
tissue. The Company has developed extensive intellectual property,
multiple products in the market and established distribution in the
United States, Europe and Asia. Certain of the Companys products have
received regulatory approvals and clearances in the United States,
Europe and China. For further information visit BSD Medicals website at www.BSDMedical.com.
About Cancer Treatment Centers of America
Cancer Treatment Centers of America, Inc. (CTCA) is a national network
of hospitals focusing on complex and advanced stage cancer. CTCA offers
a comprehensive, fully integrated approach to cancer treatment and
serves patients from all 50 states at facilities located in Atlanta,
Chicago, Philadelphia, Phoenix and Tulsa. Known for delivering the
Mother Standard of care and Patient Empowerment Medicine, CTCA
provides patients with information about cancer and their treatment
options so they can control their treatment decisions. For more
information about CTCA, go to www.cancercenter.com.
Statements contained in this press release that are not historical facts
are forward-looking statements, as defined in the Private Securities
Litigation Reform Act of 1995. All forward-looking statements are
subject to risks and uncertainties detailed in the Companys filings
with the Securities and Exchange Commission. These forward-looking
statements speak only as of the date on which such statements are made,
and the Company undertakes no obligation to update such statements to
reflect events or circumstances arising after such date.

Information Source: Business Wire